U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07161011) titled 'Phase 2b Controlled Study of Dosing Techniques - Part B' on Aug. 29.
Brief Summary: Double-masked, dose-response of two concentrations of IVW-1001
Study Start Date: Oct. 01
Study Type: INTERVENTIONAL
Condition:
Dry Eye
Intervention:
DRUG: IVW-1001 Ophthalmic Eyelid Wipe 0.2%
Low dose
DRUG: IVW-1001 Ophthalmic Eyelid Wipe 0.4%
High dose
Recruitment Status: NOT_YET_RECRUITING
Sponsor: IVIEW Therapeutics Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....